Implementing screening for chronic kidney disease (CKD) in the primary care setting can help identify patients who may benefit from upstream interventions and medications to reduce their risk of kidney failure, said Joseph Vassalotti, MD, clinical professor at Icahn School of Medicine at Mount Sinai and chief medical officer of the National Kidney Foundation.
Implementing screening for chronic kidney disease (CKD) in the primary care setting can help identify patients who may benefit from upstream interventions and medications to reduce their risk of kidney failure, said Joseph Vassalotti, MD, clinical professor at Icahn School of Medicine at Mount Sinai and chief medical officer of the National Kidney Foundation.
Transcript
What are the advantages of outlining CKD treatment recommendations according to patients’ disease class?
I think that because kidney disease is something that nephrologists have thought a lot about, that we focused a lot on the interventions being the nephrology consult, and that’s very important. That’s one of the benefits of this study is that we were able to allocate the nephrology consults according to the severity of the disease. But we also included upstream interventions that really occur in the primary care space before the patient transitions to nephrology for things like blood pressure control and diabetes control, pharmacy intervention, medical nutrition therapy—these are interventions that the primary care clinician can employ. And then now we have medication classes, like ACE [angiotensin-converting enzyme] inhibitors and angiotensin receptor blockers, for hypertension with high levels of albuminuria, that have strong evidence from randomized controlled trials that they attenuate the progression of kidney disease, that they reduce the onset of end-stage renal disease, and that they reduce cardiovascular events and mortality.
The opportunity to incorporate those therapies based on the risk stratification with the 2 tests is really important to emphasize. One aspect that we didn’t study is there is a new class of drugs called SGLT2 [sodium-glucose cotransporter-2] inhibitors for diabetes, because we designed the study really before some of the randomized trials came out. That is another opportunity, I think, for type 2 diabetes and population health and chronic kidney disease, is this class of medications reduces cardiovascular events, particularly heart failure, reduces the risk of cardiovascular death, and actually reduces the risk of kidney disease progression and kidney failure.
Bringing Connectivity to the Specialty Pharmacy Workflow
May 2nd 2024In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized the need to simplify the prescribing workflow for specialty medication through proactive messaging, automation, and interoperability.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More